Compare PubMatic Inc (PUBM) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
PubMatic Inc vs Revvity Inc — how do they compare? PubMatic Inc trades at $18.73 (market cap $850.88M), while Revvity Inc trades at $155 (market cap $16.98B). The key difference: Revvity Inc is far larger — about 20× PubMatic Inc's market cap, and Revvity Inc pays a 0.18% dividend while PubMatic Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold PubMatic Inc for 40 Days and Revvity Inc for 12 Days on average.
| PUBM | RVTY | |
|---|---|---|
Market Cap | $850.88M | $16.98B |
Volume | 997,698 | 1,456,900 |
Sector | Technology | Health |
52-Week High | $19.18 | $157.36 |
52-Week Low | $6.28 | $82.26 |
Typical Hold Time | 40 Days | 12 Days |
Enterprise Value | $754.01M | $19.30B |
Dividend Yield | — | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PubMatic (PUBM) trades at $18.72, up 0.81% with bullish technical signals from moving averages. The company shows mixed fundamentals with strong revenue growth but negative profitability metrics, including a -4.66% net margin. Recent Q2 2026 earnings beat expectations with -$0.03 EPS versus -$0.18 expected, while analyst consensus remains strongly positive with 11 buy ratings and a $19.89 price target. Operating cash flow improved to $81M in 2025, supporting business stability.
The outlook suggests potential upside near analyst targets, though profitability challenges and CFO transition pose risks. Revenue growth in mobile app and CTV segments provides catalysts, while high P/E of 132 indicates premium valuation. Investment opportunity exists for growth-focused investors tolerant of current losses, with sentiment supported by AI-driven ad tech adoption.
RVTY trades at $155.01, up 0.92% with a bullish technical outlook. The stock shows strong earnings momentum with three consecutive quarterly beats and maintains solid profitability with 54.98% gross margins. Recent developments include new product launches in Europe and strategic acquisitions to expand metabolic disease research capabilities.
The investment case balances premium valuation (P/E 73.15) against consistent execution and growth initiatives. Key risks include China market pressures and margin compression, while analyst consensus remains positive with 52% buy ratings. Upside potential exists if Q3 earnings meet expectations in November.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About PubMatic Inc
PubMatic Inc is engaged in the digital advertising business. The company provides a specialized cloud infrastructure platform that enables real-time programmatic advertising transactions. The platform helps independent app developers and publishers to control and maximize their digital advertising businesses.
Read more on PUBM →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
